(Sharecast News) - Pharmaceutical company GlaxoSmithKline has revealed positive interim Phase 2 results for its adjuvanted Covid-19 vaccine candidate, developed in partnership with Canadian biopharmaceutical firm Medicago.
GlaxoSmithKline said on Tuesday that the results were part of an ongoing Phase 2/3 study but had reiterated the "promising profile" observed during Phase 1 testing, with immunogenicity, as measured by the neutralising antibody titer, being about ten times higher than those in a panel of sera from patients recovering from Covid-19.
The FTSE 100-listed firm also highlighted that no related severe adverse events were reported and reactogenicity was said to be "generally mild to moderate" and "short in duration".
Thomas Breuer, chief medical officer of GSK's vaccines unit, said: "We are delighted to see that the results suggest a very strong immune response. Medicago's Covid-19 vaccine candidate combined with GSK's pandemic adjuvant was also well-tolerated, reinforcing its potential benefits.
"We now look forward to the outcome of the ongoing Phase 3 trial of this refrigerator-stable vaccine candidate as the next step forward in our contribution to the global response to the pandemic."
As of 0815 BST, GSK shares were down 0.30% at 1,375.40p.
Glaxosmithkline (GSK)20 Jun 2024 16:01
Industry groups back drugmakers' appeal in Zantac cancer lawsuits
June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has rece...
